Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of
xB 3 -001, the Company’s Lead Investigational Candidate to Treat Brain Cancer
Bioasis will draw on WuXi Biologics’ expertise in developing complex biologic molecules for production of
xB 3 -001 to support analytical development, formulation and IND-enabling in vivo
studies
BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) and WUXI BIOLOGICS (2269.HK) today announced an initial strategic collaboration for the development and
manufacturing of xB3-001, Bioasis’ lead investigational biological candidate to treat brain cancer.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005460/en/
Bioasis is a biopharmaceutical company developing xB3, a proprietary platform technology for the delivery of
therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical-need, including
brain cancers and neurodegenerative diseases.
Headquartered in Wuxi city, Jiangsu province, China, WuXi Biologics is a leading global platform company providing end-to-end
solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing to benefit
patients around the world.
“The initiation of manufacturing for xB3-001 is a pivotal milestone for Bioasis as we look to advance our lead
program in HER2+ breast cancer brain metastases,” said Mark Day, Ph.D., president and chief executive officer, Bioasis. “WuXi
Biologics’ expertise and experience in manufacturing biologics is instrumental to Bioasis in developing our pipeline.”
The delivery of most biologics across the BBB and into the brain has been the single greatest challenge to treating brain
diseases. Bioasis is engineering its first biologic product candidate, xB3-001, to overcome this obstacle in brain
cancer. Manufacturing these sophisticated therapies requires a tailor-made approach, with expertise and agility in cell line,
process and formulation development.
“We are excited to take on this work with Bioasis to enable them bringing innovative therapies to patients suffering from brain
cancer,” said Dr. Chris Chen, chief executive officer, WuXi Biologics. “This collaboration allows us to leverage our expertise
across biological drug development and anticipate Bioasis’ needs as they move from pre-clinical to clinical and beyond.”
Through this partnership Bioasis will have access to WuXi Biologics’ extensive expertise and technologies from cell line
construction and development, cell culture process development, purification process development and formulation development. WuXi
Biologics will focus on ensuring that Bioasis’ drug product candidates are manufactured with optimal formulation, stability and
exceptional quality for the clinic.
About WuXi Biologics
WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering
end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial
manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and
value proposition to our global clients. For more information on WuXi Biologics, please visit www.wuxibiologics.com.
About Bioasis
Bioasis Technologies Inc. is a biopharmaceutical company developing xB3, a proprietary platform technology for the
delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders, including brain cancers and
neurodegenerative diseases. The delivery of therapeutics across the BBB represents the final frontier in treating neurological
disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for
brain-related diseases and disorders. The company maintains headquarters in Richmond, BC, Canada with offices in Guilford, Conn.,
United States. Bioasis trades on the TSX Venture Exchange under the symbol “BTI” and on the OTCQB under the symbol “BIOAF.” For
more information about the company please visit www.bioasis.ca or www.bioasis.us.
Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based
on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”,
“continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known
and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results,
to be materially different from any future results, events or developments express or implied by such forward-looking statements or
information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the
ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause
such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any
future events or results expressed or implied by such statements and information include, but are not limited to, the risks and
uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted
corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional
capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able
to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial
manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com . Given these risks and uncertainties, you are cautioned not to place undue reliance on such
forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking
statements and information made herein are based on our current expectations and we undertake no obligation to revise or update
such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.
“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
WuXi Biologics
Jia Li, Corporate Communications, Senior Manager
+86-21-2066-4528
li_jia0102@wuxiapptec.com
or
Bioasis Technologies, Inc.
Catherine London
+1-917-763-2709
Catherine@bioasis.us
View source version on businesswire.com: https://www.businesswire.com/news/home/20180521005460/en/